Galectin Therapeutics Appoints Dr. Henry Brem to Board, Bolstering Clinical and Translational Expertise Ahead of Key Milestones
NORCROSS, Ga., March 17, 2026 – Galectin Therapeutics Inc. (NASDAQ:GALT), a leader in galectin-3-targeted therapies for patients with MASH cirrhosis and portal hypertension, today announced a significant addition to its Board of Directors with the appointment of Henry Brem, M.D. as an independent director. This strategic move is aimed at strengthening the company’s leadership as it advances its late-stage clinical programs and prepares for potentially market-moving milestones.
Key Highlights of the Announcement
- Appointment of Dr. Henry Brem: Dr. Brem is a world-renowned neurosurgeon-scientist, currently the Henry Brem Professor of Neurosurgery at Johns Hopkins University. He previously led the Department of Neurosurgery at Johns Hopkins and serves as Co-Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center.
- Proven Track Record: Dr. Brem has a distinguished history in translational medicine, including the development of image-guided neurosurgical techniques and innovative localized drug delivery systems such as the FDA-approved Gliadel® wafer for brain tumors.
- Scientific Contributions: With over 416 peer-reviewed publications, multiple patents, and more than four decades of continuous NIH funding, Dr. Brem is recognized as a member of the National Academy of Medicine and has received numerous honors for his clinical and research achievements.
Potential Shareholder Impact and Price-Sensitive Considerations
- Strategic Board Strengthening: The appointment of Dr. Brem signals Galectin’s commitment to strengthening its scientific and clinical leadership at a critical juncture. His expertise in advancing therapies through complex clinical development and regulatory approval is expected to be invaluable as the company prepares for upcoming milestones, including data readouts and regulatory interactions for its lead asset, belapectin.
- Lead Program – Belapectin: Galectin’s primary focus is on belapectin, a galectin-3 inhibitor with Fast Track designation from the FDA for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis. This is the most advanced stage of MASH-related fibrosis, representing a significant unmet medical need and a potentially lucrative market opportunity if successful.
- Cancer Immunotherapy Pipeline: In addition to liver disease, Galectin is exploring combination immunotherapy approaches for advanced head and neck cancers and other malignancies. The company’s ability to progress these programs will depend on securing suitable development partners, which could present future catalysts for the stock if successful collaborations are announced.
- Upcoming Data and Financial Position: The company cautions that the outcome of its NAVIGATE trial and other clinical studies remains uncertain. Success in these trials, regulatory approvals, and the ability to secure partnerships or raise additional capital are all key factors that could materially impact the share price. Conversely, delays, negative trial outcomes, or funding challenges could have a negative effect.
Forward-Looking Statements and Risks
Galectin Therapeutics reminds investors that statements regarding the future development and approval of belapectin, as well as the success of its cancer immunotherapy programs, are forward-looking and subject to significant risks and uncertainties. Important risk factors include the possibility that clinical trials may not yield positive results in a timely manner or at all, potential regulatory challenges, manufacturing scale-up issues, and the company’s ongoing need to manage operating losses and secure additional funding for its programs.
Investor Contact Information
For more information, visit www.galectintherapeutics.com.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed. Investors should consult Galectin Therapeutics’ filings with the SEC, including the most recent Annual Report on Form 10-K and subsequent filings, for additional information on risks and uncertainties. No obligation is undertaken to update forward-looking statements in light of new information or future events.
View GALECTIN THERAPEUTICS INC Historical chart here
